ADHD (Attention-deficit hyperactivity disorder)
Current Care Summary |  Published: 2017-05-31  
Working group appointed by the Finnish Medical Society Duodecim, the Finnish Association of Paediatric Neurology, the Finnish Society for Child and Adolescent Psychiatry and the Finnish Society for Adolescent Psychiatry
Print

ADHD (Attention-deficit hyperactivity disorder)

Current Care Summary
31.5.2017
Working group appointed by the Finnish Medical Society Duodecim, the Finnish Association of Paediatric Neurology, the Finnish Society for Child and Adolescent Psychiatry and the Finnish Society for Adolescent Psychiatry

Current Care Guideline «ADHD (aktiivisuuden ja tarkkaavuuden häiriö)»1 and Summary «ADHD (aktiivisuuden ja tarkkaavuuden häiriö)»2 in Finnish

The updated guideline covers diagnosis and treatment of ADHD in children, adolescents, and adults. In all age groups, diagnosis is based on typical core symptoms (inattention, hyperactivity, impulsivity), and functional impairment in the course of person’s life. Psychiatric comorbidity is common, and must be taken into account.

Treatment should be tailored individually to include psychoeducation, psychosocial interventions and support, and/or medication. Depending on age, collaboration with family, day-care/school, and primary/occupational health care should be considered. Evidence-based and licensed drug treatments for ADHD are atomoxetine, lisdexamfetamine, methylphenidate, and, for children and adolescents, guanfacine.

Anita Puustjärvi

Sami Leppämäki

Vesa Närhi

Leena Pihlakoski

Maria Sumia

Maarit Virta

Arja Voutilainen

Arja Tuunainen

Current Care Guidelines are independent, evidence-based clinical practice guidelines. These national guidelines cover important issues related to Finnish health, medical treatment as well as prevention of diseases. Learn more